The Asia-Pacific neurological disorder drugs market is projected to grow at a significant CAGR during the forecast period (2020-2026). The key factors driving the growth of the market include the rising geriatric population, increased prevalence of neurological disorders coupled with the development of novel drugs and technologies for drug development. In the Asia-Pacific region, economies such as China, India, and Japan have a major number of geriatric populations. For instance, Japan has the world’s oldest population, as per the Weforum 2019. The country’s almost a third of its population is over 65; there are 2.3 billion people in their 70s. This population pool serves as a major target audience for the market as this age group is at increased risk of developing neurological disorders.
Get Free Sample Copy @ https://www.omrglobal.com/request-sample/asia-pacific-neurological-disorder-drugs-market
The Asia-Pacific neurological disorder drugs market is segmented on the basis of disorder type into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington disease, and others. Amongst the disorder type segment, Parkinson’s disease segment is projected to hold a lucrative share in the market. The segmental growth of the market is attributed to the increased prevalence of Parkinson’s disease among people across the globe. A broad range of drugs is used for the treatment of neurological disorders, some of which include analgesics, antihypertensive, anticholinergic, hypnotic & sedatives, and others.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/asia-pacific-neurological-disorder-drugs-market
Geographically, the Asia-Pacific neurological disorder drugs market is analyzed into China, India, Japan, and the Rest of Asia-Pacific. China is estimated to grow significantly during the forecast period. Further, Cadila Healthcare Ltd., Astellas Pharma Ltd., Cipla Ltd., Sun Pharmaceuticals Industries ltd., Teva Pharmaceuticals Industries Ltd., and Takeda Pharmaceutical Co., Ltd. are some of the prominent players operating in the Asia-Pacific neurological disorder drugs market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market
Market Segmentation
Asia-Pacific Neurological Disorder Drugs Market by Disorder Type
• Alzheimer’s Disease
• Parkinson’s Disease
• Multiple Sclerosis
• HuntingtonDisease
• Others
Regional Analysis
• China
• India
• Japan
• Rest of Asia-Pacific
Company Profiles
Alembic Pharmaceuticals Ltd.
• Overview
• Alembic Pharmaceuticals in Neurological Disorder Drug Landscape
• Recent Developments
• Astellas Pharma Inc.
• AstraZeneca Plc
• Cadila Healthcare Ltd.
• Cipla Ltd.
• Daiichi Sankyo Espha Co., Ltd.
• Eisai Co. Ltd.
• GlaxoSmithKline Plc
• Novartis International AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Rusan Pharma Ltd.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-neurological-disorder-drugs-market About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404